ResMed shares on watch after quarter results

Company News

by Rachael Jones

For the three months ending December 31, ResMed (ASX:RMD) delivered revenue of US$651.1 million, which was an increase of 8 per cent on the prior corresponding period.

The sleep treatment medical device net operating profit increased 8 per cent.

Revenue in the US, Canada, and Latin America, excluding Software as a Service, grew by 9 percent compared to the prior year period, driven by strong sales across their mask and device product portfolios.

Shares in Resmed (ASX:RMD) are trading 8.45 per cent lower at $15.06.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.